中医药临床优势病种探讨——膜性肾病

Expert Consensus on Clinical Diseases Responding Specifically to Traditional Chinese Medicine:Membranous Nephropathy

中医药是一座伟大的宝库,在治疗某些疑难病、危重病中具有独特优势。膜性肾病近些年来发病率逐年升高,已发展成为原发性肾小球疾病的首位病因,但其发病机制不清,现代医学常使用免疫抑制疗法,但往往面临着不良反应大、复发率高的问题。中华中医药学会邀请各位中西医临床一线专家对膜性肾病进行充分讨论后认为:膜性肾病属于中医药临床优势病种之一。该共识基于会议讨论,将中西医对膜性肾病发病机制、临床诊治的认识进行总结,并具体阐释了中医药对膜性肾病的认识及辨证治疗方案,以期提高膜性肾病的临床缓解率,为临床医师治疗膜性肾病提供参考。

Traditional Chinese medicine(TCM)is a great treasure house,exhibiting unique advantages in the treatment of some difficult and critical diseases. The incidence rate of membranous nephropathy has increased year by year in recent years,and has become the first cause of primary glomerular diseases. However,its pathogenesis is not clear. Modern medicine often uses immunosuppressive therapy,but it often faces the problems of high side effects and high recurrence rate. The China Association of Chinese Medicine(CACM)invited clinical experts of TCM and western medicine to fully discuss membranous nephropathy,which was later confirmed to be one of the clinical diseases responding specifically to TCM. Apart from summarizing the pathogenesis and clinical diagnosis and treatment of membranous nephropathy in both TCM and western medicine, this paper also detailed TCM cognition, syndrome differentiation, and therapeutic schemes of membranous nephropathy, aiming to improve the clinical remission rate of membranous nephropathy and provide reference for its clinical treatment.